TD Waterhouse Canada Inc. raised its stake in Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) by 1.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 47,497 shares of the company’s stock after acquiring an additional 859 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Cellebrite DI were worth $1,046,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently modified their holdings of CLBT. True Wind Capital Management L.P. raised its position in shares of Cellebrite DI by 18.2% in the fourth quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company’s stock worth $305,358,000 after buying an additional 2,130,386 shares in the last quarter. FMR LLC raised its position in Cellebrite DI by 89.1% during the fourth quarter. FMR LLC now owns 10,621,344 shares of the company’s stock valued at $233,988,000 after purchasing an additional 5,004,587 shares in the last quarter. Pertento Partners LLP lifted its position in Cellebrite DI by 26.7% in the 4th quarter. Pertento Partners LLP now owns 2,975,374 shares of the company’s stock worth $65,547,000 after buying an additional 626,373 shares during the last quarter. Pembroke Management LTD boosted its stake in Cellebrite DI by 4.4% in the fourth quarter. Pembroke Management LTD now owns 1,992,432 shares of the company’s stock worth $43,893,000 after buying an additional 84,087 shares in the last quarter. Finally, Crescent Park Management L.P. grew its position in Cellebrite DI by 8.3% during the fourth quarter. Crescent Park Management L.P. now owns 1,862,482 shares of the company’s stock valued at $41,030,000 after acquiring an additional 142,534 shares during the last quarter. 45.88% of the stock is owned by institutional investors.
Cellebrite DI Trading Up 2.6 %
Shares of Cellebrite DI stock opened at $19.56 on Friday. The business has a fifty day simple moving average of $18.75 and a two-hundred day simple moving average of $20.10. The firm has a market capitalization of $4.68 billion, a P/E ratio of -14.07, a P/E/G ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a 12 month low of $10.25 and a 12 month high of $26.30.
Analyst Ratings Changes
A number of brokerages have recently issued reports on CLBT. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Cellebrite DI in a research note on Wednesday, April 2nd. JPMorgan Chase & Co. upped their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Finally, Lake Street Capital boosted their price target on Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a report on Friday, February 14th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $23.43.
Check Out Our Latest Report on Cellebrite DI
About Cellebrite DI
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Recommended Stories
- Five stocks we like better than Cellebrite DI
- Canada Bond Market Holiday: How to Invest and Trade
- 2 Strong Utilities Plays With Booming Earnings and Room to Grow
- What Does Downgrade Mean in Investing?
- Why Smart Investors Don’t Panic in Election Season
- How to Most Effectively Use the MarketBeat Earnings Screener
- Now Is the Time to Buy ServiceNow—The Rebound Is Real
Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report).
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.